Navigation Links
Cohera Medical Names Richard L. Wonsettler as Company's First CFO
Date:6/30/2008

PITTSBURGH, June 30 /PRNewswire/ -- Cohera Medical Inc. today named Richard L. Wonsettler to the newly created position of vice president of finance and CFO.

The addition of Wonsettler, who has nearly 20 years of financial management experience with emerging private and public companies, comes at a time that Cohera Medical is preparing to enter the clinical stage of development with its lead surgical adhesive product, TissuGlu(R).

"We are entering an important phase in the company's growth," said Patrick Daly, president and CEO of Cohera Medical. "In conjunction with our product development activities, we are ramping up our financing activities. Richard has the proven experience in working with companies in positions similar to ours. He will be integral to our plans moving forward."

Prior to joining Cohera Medical, Wonsettler was the CFO and treasurer of Active Media/ClubCom Inc., venture-capital-backed, start-up companies in Pittsburgh for which he built the accounting and treasury departments. Before this, Wonsettler worked with Wexford, Penn.-based SMT Health Services Inc. (SMT) as CFO and treasurer. He was the head of SMT's finance department when the company was owned by private equity firm Apollo Management L.P. Earlier in his career, Wonsettler was an audit professional with KPMG L.L.P. in Pittsburgh.

Wonsettler is a certified public accountant. He received a bachelor's degree in accounting, summa cum laude, from Washington and Jefferson College in Washington, Penn.

About Cohera Medical

Cohera Medical Inc. is a Pittsburgh-based company that is developing a revolutionary line of wound management products and surgical adhesives. Cohera Medical's products are based on a unique chemical design that is purely synthetic, easy to use, biocompatible and fully resorbable. The company's lead product in development, TissuGlu, is a sprayable bonding agent for plastic surgery procedures. TissuGlu adheres flaps of tissue aft
'/>"/>

SOURCE Cohera Medical Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Data Published in Plastic and Reconstructive Surgery Show Cohera Medicals Surgical Adhesive, TissuGlu(R), Prevents Seroma Formation in Animal Abdominoplasty Model
2. MYSTERY ER Season 2 Takes Viewers Behind the Curtain for Real-Life Medical Mysteries on Discovery Health
3. WaferGens SmartChip(TM) Real-Time PCR System to Begin Alpha Testing at University of Pittsburgh Medical School
4. Southern Home Medical Equipment Completes 1-for-1,000 Reverse Split and Begins Trading Under New Symbol SHOM
5. Medical Machines Online Announces the Overstock and Release of a New ECG Machine
6. Urgent Care Provider NextCare Introduces CareForToday Medical Insurance Plan
7. Grubb & Ellis Healthcare REIT Acquires SouthCrest Medical Plaza in Stockbridge, Ga.
8. Response Biomedical Corporation Announces Strategic Partnership with Roche Diagnostics To Commercialize Cardiovascular Tests
9. Encore Medical Staffing of Greenville Signs Seventh Staffing Agreement
10. Pathway Medical Technologies Awarded New Patent for Pathway PV(TM) Atherectomy System for Improved Differential Cutting
11. Exclusive Resort Community Looks to MedeFile to Provide Members With Access to Medical Records Anytime, Anywhere
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 2Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 3Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 4Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 5Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 2Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 3CareFusion Announces Six New Pyxis(R) Technologies at the ASHP Midyear Clinical Meeting and Exhibition 2CareFusion Announces Six New Pyxis(R) Technologies at the ASHP Midyear Clinical Meeting and Exhibition 3VYVANSE CII provided significant efficacy at 14 hours in adults with ADHD 50532 1VYVANSE CII provided significant efficacy at 14 hours in adults with ADHD 50532 2VYVANSE CII provided significant efficacy at 14 hours in adults with ADHD 50532 3VYVANSE CII provided significant efficacy at 14 hours in adults with ADHD 50532 4Colorectal cancer 9090 1Genetically engineered mice yield clues to knocking out cancer 9086 1Genetically engineered mice yield clues to knocking out cancer 9086 2